Increlex for growth failure in children

Ipsen has launched Increlex (mecasermin) for the long-term treatment of growth failure in children and adolescents with severe primary insulin-like growth factor-1 (IGF-1) deficiency.

PHARMACOLOGY
Mecasermin is a human IGF-1 produced by recombinant DNA technology.

IGF–1 is the principal hormonal mediator of growth. In target tissues, IGF–1 activates the IGF–1 receptor, leading to intracellular signalling to induce and support statural growth. IGF–1 induces the uptake of glucose, fatty acids and amino acids so that metabolism supports growing tissues.

Further information: Ipsen 01753 627777

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases